ML385: Selective NRF2 Inhibitor for Cancer and Redox Research

Executive Summary: ML385 (CAS 846557-71-9) is a highly selective small molecule inhibitor of the transcription factor NRF2, featuring an IC₅₀ of 1.9 μM in A549 non-small cell lung cancer (NSCLC) cells. It is insoluble in water and ethanol but dissolves in DMSO at concentrations ≥13.33 mg/mL. APExBIO supplies ML385 (SKU B8300) for advanced cancer and redox research applications. In vitro and in vivo studies demonstrate that ML385 downregulates NRF2-dependent gene expression, reduces tumor growth, and sensitizes tumor models to carboplatin. ML385 is a validated tool for interrogating NRF2-driven antioxidant response pathways and addressing therapeutic resistance in cancer models (APExBIO ML385; Zhou et al., 2024).

Biological Rationale

Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor critical for regulating cellular antioxidant responses and detoxification pathways. NRF2 upregulates genes involved in redox homeostasis, including those encoding NADPH-generating and antioxidant enzymes. Elevated NRF2 activity is implicated in cancer progression, multidrug resistance, and protection against oxidative injury (Zhou et al., 2024). In non-small cell lung cancer (NSCLC), NRF2 hyperactivity correlates with poor prognosis and resistance to chemotherapy. Modulating NRF2 function provides a strategic entry point for investigating both cancer biology and metabolic disease mechanisms.

Mechanism of Action of ML385

ML385 acts as a selective inhibitor of NRF2 by directly binding to the Neh1 DNA-binding domain of the NRF2 protein, thereby blocking its transcriptional activity. This inhibition prevents NRF2 from upregulating its target antioxidant and detoxification genes, such as NQO1, HO-1, and FTH1. In A549 NSCLC cells, ML385 produces a dose- and time-dependent suppression of NRF2-driven gene expression. In vivo, ML385 reduces NRF2 pathway signaling, decreases tumor burden, and enhances the efficacy of chemotherapeutic agents like carboplatin when administered in combination (APExBIO ML385).

Evidence & Benchmarks

• ML385 exhibits an IC₅₀ of 1.9 μM for NRF2 inhibition in A549 NSCLC cells (APExBIO ML385).
• In NSCLC mouse models, ML385 (100 mg/kg/day, i.p.) reduces tumor volume and metastasis, especially when combined with carboplatin (Zhou et al., 2024).
• ML385 is insoluble in water and ethanol, with a solubility of ≥13.33 mg/mL in DMSO, facilitating high-concentration stock preparation (APExBIO ML385).
• ML385 downregulates NRF2-dependent genes (e.g., NQO1, HO-1, FTH1) in cell-based and animal models, as measured by RT-qPCR and Western blot (Zhou et al., 2024).
• Combining ML385 with Poria cocos polysaccharides (PCP) or ferrostatin-1 demonstrates synergistic effects in modulating ferroptosis and oxidative stress in alcoholic liver disease models (Zhou et al., 2024).

This article extends on "ML385: Selective NRF2 Inhibitor for Cancer Research & Beyond" by providing updated clinical and in vivo benchmarks and a detailed analysis of ML385’s application in complex disease models. For mechanistic insights, readers may also refer to "ML385 and the NRF2 Frontier", which focuses on translational strategy and next-generation research guidance, whereas this article aggregates recent peer-reviewed findings and practical usage notes.

Applications, Limits & Misconceptions

ML385 is primarily used in cancer research to interrogate NRF2 signaling, study oxidative stress regulation, and explore mechanisms underlying therapeutic resistance. Its validated efficacy in both in vitro and in vivo models makes it suitable for:

• Non-small cell lung cancer (NSCLC) research and anti-cancer drug combination studies.
• Oxidative stress modulation and ferroptosis pathway interrogation in liver and metabolic disease models.
• Screening NRF2-dependent gene expression and pathway activity in cell culture systems.

However, ML385 is not a pan-reactive redox modulator and does not inhibit other transcription factors involved in oxidative stress, such as NF-κB (Zhou et al., 2024). Its specificity for NRF2 limits off-target effects but also constrains its use in multi-factorial pathway studies.

Common Pitfalls or Misconceptions

• ML385 is not effective in cell lines or models where NRF2 is not the primary driver of redox homeostasis.
• ML385 does not directly scavenge free radicals or act as an antioxidant; it only inhibits NRF2-driven gene transcription.
• Long-term storage of ML385 solutions can lead to compound degradation; fresh preparation is recommended.
• ML385 is insoluble in water and ethanol, requiring DMSO for stock solution preparation.
• It does not inhibit NF-κB or other unrelated transcription factors, so combinatorial signaling investigations must use additional tools.

Workflow Integration & Parameters

ML385 (SKU B8300) from APExBIO is supplied as a powder and should be dissolved in DMSO to a concentration of at least 13.33 mg/mL. For in vitro studies, ML385 is typically used at concentrations ranging from 1 μM to 10 μM, depending on cell type and experimental design. For in vivo applications, mouse models have used 100 mg/kg/day via intraperitoneal injection. Storage at -20°C is recommended, and solutions should be freshly prepared to prevent degradation (APExBIO ML385).

Integration into workflow requires validation of NRF2 pathway activation status; ML385 is most effective where NRF2 is constitutively active or upregulated. Downstream readouts commonly include RT-qPCR for NRF2 target genes, Western blot for protein expression, and functional assays for oxidative stress or cell viability. For additional troubleshooting and workflow guidance, see "Solving Lab Assay Challenges with ML385", which details scenario-driven advice for maximizing assay reproducibility.

Conclusion & Outlook

ML385, as a selective NRF2 inhibitor, is a robust reagent for dissecting the NRF2 signaling pathway in cancer and metabolic disease models. Its validated chemical and biological profile ensures reproducibility and specificity in both cell-based and animal studies. ML385 is integral to studies that seek to overcome therapeutic resistance and better understand antioxidant response regulation in oncology. As redox biology and cancer research advance, ML385 will continue to support translational discoveries and preclinical validation. For ordering and detailed specifications, refer to the official APExBIO ML385 product page.